Clinical Trials Browser

Phase 3 × Withdrawn × Pharmaceutical Preparations × Clear all

NCT03791918 2019-05-02

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

Phase 3 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular